Platelet aggregation pathway via eicosanoid modulation

The platelet aggregation pathway via eicosanoid modulation encompasses the molecular and cellular events by which eicosanoids, derived primarily from arachidonic acid metabolism through the actions of cyclooxygenase (COX) and lipoxygenase (LOX) enzymes, regulate platelet activation and aggregation. The key pro-aggregatory eicosanoid is thromboxane A2 (TXA2), synthesized by platelet COX-1, which binds to thromboxane receptors on platelets to promote their activation and recruit additional platelets. Counter-regulatory eicosanoids include prostacyclin (PGI2), generated by endothelial cells, which inhibits platelet aggregation and promotes vasodilation. Other eicosanoids, such as prostaglandin D2, E2, and various HETE species (e.g., 12-HETE), can have context-dependent effects, either enhancing or inhibiting aggregation[1][3][7]. This complex network is targeted therapeutically by agents like aspirin (inhibiting COX-1/TXA2 synthesis) and forms a key mechanism in the prevention and treatment of cardiovascular disease, but is associated with bleeding risk due to impaired hemostasis[3][7].

Other names

Platelet eicosanoid signalingPlatelet eicosanoid pathwayPlatelet aggregation via eicosanoids

Inhibition of cyclooxygenase (prevents thromboxane A2 formation, reducing platelet aggregation); Antagonism of thromboxane receptor (blocks TXA2-induced aggregation); Modulation of prostaglandin signaling (pro- or anti-aggregatory)